Beroni Group (OTCQX:BNIGF) (NSX:BTG) today announced that it received the first commercial order for its proprietarily developed SARS-CoV-2 Antibody Detection Kit from Forsitech Inc., a pharmaceutical trading company based in Japan.
Beroni Group Limited
Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that further to its announcement on August 4, 2020 regarding the development of a medical solution utilizing nanobody technology for COVID-19, it has just signed an agreement with GenScript Biotech Corporation
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) today announced its further progress on the development of a medical solution using nanobody technology for the COVID-19 coronavirus in collaboration with Tianjin University in China.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it is collaborating with Forsitech Inc. and Standard Capital Co., Ltd to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has appointed Dr. Richard Buchta as an independent non-executive director of the Company
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that, the Company has completed the issue of 2,390,000 fully paid ordinary shares to the Directors, employees and scientists.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has raised US$2.97 million via the issue of convertible notes to professional and sophisticated investors in Japan.